

10/634,289

- 2 -

PC25244A

**REMARKS**

Claims 1, 2, and 4 to 12 are allowed.

***Comments on Statement of Reasons for Allowance***

In item 2 of the Notice, the Examiner stated the following reason for allowance:

The rejection for claims 1, 2, 4, and 9 under 35 U.S.C. § 102(b) as allegedly being anticipated by Hadley et al. (U.S. 6,245,778) is withdrawn in view of the amendment of Q, which amendment thereby excludes Hadley et al.'s species compounds wherein Q is C(O)NR<sup>6</sup>, R<sup>1</sup> is substituted phenyl, Y is CH<sub>2</sub>, and R<sup>2</sup> is alkyl.

In the non-final Office Action mailed January 21, 2005, claims 1, 2, 4, and 9 were rejected under 35 U.S.C. § 102(b) as allegedly being anticipated by Hadley et al. because it was asserted that the compounds of claim 2 (columns 22-23), and the pharmaceutical compositions thereof, of Hadley et al. are encompassed by the instant claims wherein Q is NR<sup>6</sup>C(O), R<sup>1</sup> is substituted phenyl, Y is CH<sub>2</sub>, and R<sup>2</sup> is alkyl. Applicants disagree. As Applicants pointed out previously,<sup>1</sup> the compounds of Hadley et al. contain the group C(O)-N(H), whereas the Q group of original claim 1 of the present application has the reverse orientation, N(R<sup>6</sup>)C(O). The C(O)-N(H) group of Hadley et al. is not found in the Q of original claim 1 of the present application, and thus Hadley et al. does not anticipate claims 1, 2, 4, or 9 under 35 U.S.C. § 102(b).

Respectfully submitted,

Date: August 17, 2005

Claude F. Purchase, Jr.  
Claude F. Purchase, Jr.  
Reg. No. 47,871  
Pfizer Inc.  
2800 Plymouth Road  
Ann Arbor, MI 48105  
Tel. (734) 622-1692  
Fax (734) 622-1553

<sup>1</sup> See Applicants paper, Amendment & Reply Under 35 U.S.C. § 1.111 sent on March 24, 2005.